Dermatology
Latest News
Study Finds Potential benefits of Spironolactone for Women with HS
The retrospective study included 157 women with HS who received spironolactone for at least 3 months.
Latest News
Studies Show Dupilumab Effects In Children with Both Atopic Dermatitis and Alopecia
Overall, 77.4% of patients in the trials achieved hair regrowth with dupilumab treatment.
Latest News
Study Estimates Global Prevalence of Seborrheic Dermatitis
The global prevalence in this meta-analysis was “higher than previous large-scale global estimates,’ the authors wrote.
Latest News
How Common Are Life-Threatening Infections In Infants with Pustules, Vesicles?
Among 879 consults, 183 afebrile infants were identified as having presented with pustules, vesicles, and/or bullae.
Latest News
Topical PDE4 Inhibitor Now Approved for Atopic Dermatitis in Children, Adults
Among children and adults who participated in the INTEGUMENT studies for 28 and 56 weeks, 61.3% and 65.7% saw a 75% reduction in their Eczema Area...
From the Journals
Urticaria Linked to Higher Cancer Risk, Study Finds
Researchers compare the incident cancer risk between patients with urticaria and the general population using data from Danish healthcare...
Latest News
Study Finds Variations in Pediatric Dermatologists Who Accept Medicaid
More research is needed on “the impact on health outcomes when specialty services are unavailable,” the authors wrote.
News from the FDA/CDC
Pyzchiva Receives FDA Approval as Third Ustekinumab Biosimilar
The biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025.
Latest News
FDA Approves Topical Anticholinergic for Axillary Hyperhidrosis
Approval was based on results from two phase 3 studies that enrolled 710 patients with primary axillary hyperhidrosis.
Latest News
Atopic Dermatitis: Study Compares Prevalence by Gender, Age, and Ethnic Background
“Results are important for us to consider targeted strategies to address AD burden,” said Raj Chovatiya, MD, PhD....
Latest News
Topical Ruxolitinib Effective for AD in Study of Children Ages 2-11 years
No treatment-related interruptions, discontinuations, or serious adverse events were observed between baseline and week 52.